Literature DB >> 18449948

Transcription factor Sp1 dysregulation in Alzheimer's disease.

Bruce A Citron1, John S Dennis, Ross S Zeitlin, Valentina Echeverria.   

Abstract

Altered gene expression occurs in central nervous system disorders, including Alzheimer's disease (AD). Transcription factor Sp1 may be involved insofar as it can regulate the expression of several AD-related proteins, including amyloid precursor protein (APP) and tau. Sp1 could itself be regulated by inflammatory and other factors associated with AD, such as interleukin-1beta. We measured an almost threefold elevation in the number of mRNA molecules of this cytokine in the AD frontal cortex. Sp1 mRNA was found to be up-regulated in these AD brains (along with Sp1-regulated COX-2), and the Sp1 increase was also seen at the protein level by Western immunoblotting. To determine whether this would also occur in transgenic mice developing AD pathology, we examined the expression of Sp1 in the cortex and hippocampus and observed higher levels of Sp1 mRNA and protein. These results indicate that elements of regulatory pathways involving transcription factor Sp1 may be useful targets for therapeutic intervention to prevent or reverse AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449948     DOI: 10.1002/jnr.21695

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  46 in total

1.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 2.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies.

Authors:  Lina Adwan; Gehad M Subaiea; Riyaz Basha; Nasser H Zawia
Journal:  J Neurochem       Date:  2014-10-18       Impact factor: 5.372

Review 4.  miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy.

Authors:  Hanuma Kumar Karnati; Manas Kumar Panigrahi; Ravi Kumar Gutti; Nigel H Greig; Ian A Tamargo
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 5.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

6.  Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.

Authors:  Lina Adwan; Gehad M Subaiea; Nasser H Zawia
Journal:  Neuropharmacology       Date:  2014-01-21       Impact factor: 5.250

7.  Genetic diversity and striatal gene networks: focus on the heterogeneous stock-collaborative cross (HS-CC) mouse.

Authors:  Ovidiu D Iancu; Priscila Darakjian; Nicole A R Walter; Barry Malmanger; Denesa Oberbeck; John Belknap; Shannon McWeeney; Robert Hitzemann
Journal:  BMC Genomics       Date:  2010-10-19       Impact factor: 3.969

8.  Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer's disease.

Authors:  Bruce A Citron; Jessica N Saykally; Chuanhai Cao; John S Dennis; Melissa Runfeldt; Gary W Arendash
Journal:  Am J Neurodegener Dis       Date:  2015-12-28

9.  Altered microRNA, mRNA, and Protein Expression of Neurodegeneration-Related Biomarkers and Their Transcriptional and Epigenetic Modifiers in a Human Tau Transgenic Mouse Model in Response to Developmental Lead Exposure.

Authors:  Anwar M Masoud; Syed W Bihaqi; Bothaina Alansi; Miriam Dash; Gehad M Subaiea; William E Renehan; Nasser H Zawia
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice.

Authors:  Gehad M Subaiea; Lina I Adwan; Aseef H Ahmed; Karen E Stevens; Nasser H Zawia
Journal:  Neurobiol Aging       Date:  2013-04-30       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.